Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 44.77% is in line with its 5-year average of 44.57%, around the middle of its 5-year range (38.72%–49.97%).
0.37% above its 12-month average of 44.61%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 48.98%.
GROSS MARGIN
44.77%
GROSS MARGIN AVG TTM
44.61%
GROSS MARGIN AVG 3Y
43.40%
GROSS MARGIN AVG 5Y
44.57%
GROSS MARGIN AVG 10Y
45.51%
GROSS MARGIN AVG 15Y
47.98%
GROSS MARGIN AVG 20Y
49.07%
CURRENT VS TTM AVG
+0.37%
CURRENT VS 3Y AVG
+3.16%
CURRENT VS 5Y AVG
+0.44%
CURRENT VS 10Y AVG
-1.64%
CURRENT VS 15Y AVG
-6.69%
CURRENT VS 20Y AVG
-8.76%
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
+10.71%
vs the sector median at left
Market Cap
$1.60B
Gross Margin
53.89%
TTM Avg
45.92%
3Y Avg
-11.61%
5Y Avg
-9.29%
Market Cap
$1.61B
Gross Margin
87.11%
TTM Avg
89.24%
3Y Avg
90.16%
5Y Avg
89.75%
Market Cap
$1.62B
Gross Margin
51.01%
TTM Avg
55.14%
3Y Avg
57.28%
5Y Avg
56.79%
Market Cap
$1.64B
Gross Margin
66.15%
TTM Avg
69.48%
3Y Avg
67.43%
5Y Avg
67.56%
Market Cap
$1.54B
Gross Margin
97.47%
TTM Avg
96.23%
3Y Avg
48.12%
5Y Avg
65.41%
Market Cap
$1.53B
Gross Margin
51.26%
TTM Avg
45.83%
3Y Avg
28.18%
5Y Avg
37.38%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omnicell, Inc. (OMCL) | $1.59B | 44.77% | 44.61% | 43.40% | 44.57% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.60B | 53.89% | 45.92% | -11.61% | -9.29% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | 87.11% | 89.24% | 90.16% | 89.75% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 51.01% | 55.14% | 57.28% | 56.79% |
| Septerna Inc (SEPN)vs › | $1.63B | 99.57% | 100.00% | 75.00% | 75.00% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 66.15% | 69.48% | 67.43% | 67.56% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 73.09% | 81.06% | 86.06% | 90.71% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 97.47% | 96.23% | 48.12% | 65.41% |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 51.26% | 45.83% | 28.18% | 37.38% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | 100.00% | 100.00% | 100.00% | 66.67% |
Gross Margin
44.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 48.98% |
| 2026-03-31 | 45.30% |
| 2025-12-31 | 41.51% |
| 2025-09-30 | 43.30% |
| 2025-06-30 | 43.94% |
| 2025-03-31 | 41.14% |
| 2024-12-31 | 46.57% |
| 2024-09-30 | 43.52% |
| 2024-06-30 | 41.31% |
| 2024-03-31 | 38.72% |
| 2023-12-31 | 40.72% |
| 2023-09-30 | 44.18% |
| 2023-06-30 | 44.97% |
| 2023-03-31 | 43.02% |
| 2022-12-31 | 40.90% |
| 2022-09-30 | 45.71% |
| 2022-06-30 | 47.71% |
| 2022-03-31 | 47.06% |
| 2021-12-31 | 48.00% |
| 2021-09-30 | 49.52% |
| 2021-06-30 | 49.97% |
| 2021-03-31 | 48.56% |
| 2020-12-31 | 49.62% |
| 2020-09-30 | 45.29% |
| 2020-06-30 | 41.69% |
| 2020-03-31 | 47.73% |
| 2019-12-31 | 49.78% |
| 2019-09-30 | 49.01% |
| 2019-06-30 | 47.86% |
| 2019-03-31 | 47.95% |
| 2018-12-31 | 48.26% |
| 2018-09-30 | 48.42% |
| 2018-06-30 | 47.06% |
| 2018-03-31 | 45.15% |
| 2017-12-31 | 48.03% |
| 2017-09-30 | 45.43% |
| 2017-06-30 | 43.11% |
| 2017-03-31 | 42.64% |
| 2016-12-31 | 43.22% |
| 2016-09-30 | 46.12% |
| 2016-06-30 | 45.12% |
| 2016-03-31 | 46.75% |
| 2015-12-31 | 49.94% |
| 2015-09-30 | 50.87% |
| 2015-06-30 | 50.95% |
| 2015-03-31 | 53.08% |
| 2014-12-31 | 52.48% |
| 2014-09-30 | 52.91% |
| 2014-06-30 | 53.35% |
| 2014-03-31 | 53.55% |
| 2013-12-31 | 53.55% |
| 2013-09-30 | 55.34% |
| 2013-06-30 | 52.70% |
| 2013-03-31 | 52.08% |
| 2012-12-31 | 54.72% |
| 2012-09-30 | 54.65% |
| 2012-06-30 | 52.23% |
| 2012-03-31 | 55.73% |
| 2011-12-31 | 57.01% |
| 2011-09-30 | 53.46% |
| 2011-06-30 | 55.42% |
| 2011-03-31 | 55.37% |
| 2010-12-31 | 54.77% |
| 2010-09-30 | 53.48% |
| 2010-06-30 | 52.78% |
| 2010-03-31 | 50.93% |
| 2009-12-31 | 49.81% |
| 2009-09-30 | 50.50% |
| 2009-06-30 | 51.15% |
| 2009-03-31 | 45.63% |
| 2008-12-31 | 50.22% |
| 2008-09-30 | 50.92% |
| 2008-06-30 | 51.06% |
| 2008-03-31 | 52.09% |
| 2007-12-31 | 53.33% |
| 2007-09-30 | 54.06% |
| 2007-06-30 | 52.77% |
| 2007-03-31 | 52.41% |
| 2006-12-31 | 56.80% |
| 2006-09-30 | 54.31% |
| 2006-06-30 | 55.41% |
| 2006-03-31 | 54.65% |
| 2005-12-31 | 55.19% |
| 2005-09-30 | 58.30% |
| 2005-06-30 | 56.86% |
| 2005-03-31 | 50.02% |
| 2004-12-31 | 54.22% |
| 2004-09-30 | 58.31% |
| 2004-06-30 | 60.54% |
| 2004-03-31 | 59.69% |
| 2003-12-31 | 58.98% |
| 2003-09-30 | 59.03% |
| 2003-06-30 | 58.25% |
| 2003-03-31 | 57.18% |
| 2002-12-31 | 55.95% |
| 2002-09-30 | 55.29% |
